Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "J05AF" (37)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (J05AF) 1 products
WHO-DDD
IP
CI
Vemlidy
30
449.12
504.85
10 %
Coated tablets: Tenofovirum Alafenamidum 25 mg
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
Zidovudine (J05AF01) 3 products
WHO-DDD
DrugBank.ca
IP
CI
Retrovir AZT
200 ml
25.38
44.00
10 %
Sirup: Zidovudinum 50mg / 5ml
ViiV Healthcare GmbH
A / SL
FB
G
IP
CI
Retrovir AZT 250 mg
40 Capsule(s)
124.26
151.55
10 %
Capsules: Zidovudinum 250 mg
ViiV Healthcare GmbH
A / SL
FB
G
IP
Retrovir AZT i.v.
5 1 ampoule(s)
k.A.
Infusion solution: Zidovudinum 200mg / 20ml
ViiV Healthcare GmbH
A
FB
G
Lamivudine (J05AF05) 8 products
WHO-DDD
DrugBank.ca
IP
CI
Lamivudin-Mepha 150
60
138.32
166.85
10 %
Coated tablets: Lamivudinum 150 mg
Mepha Pharma AG
A / SL / SG
FB
G
IP
CI
Lamivudin-Mepha 300
30
138.32
166.85
10 %
Coated tablets: Lamivudinum 300 mg
Mepha Pharma AG
A / SL / SG
FB
G
L
IP
CI
Zeffix
-
T
28 Tablet(s)
59.42
81.05
10 %
Coated tablets: Lamivudinum 100 mg
GlaxoSmithKline AG
A / SL
FB
G
L
IP
CI
Zeffix
-
T
84 Tablet(s)
153.23
183.05
10 %
Coated tablets: Lamivudinum 100 mg
GlaxoSmithKline AG
A / SL
FB
G
L
IP
CI
Zeffix
240 ml
27.75
46.60
10 %
Solution (oral): Lamivudinum 5 mg/ml
GlaxoSmithKline AG
A / SL
FB
G
IP
CI
3TC 150 mg
60 Tablet(s)
162.73
191.90
10 %
Coated tablets: Lamivudinum 150 mg
ViiV Healthcare GmbH
A / SO
FB
G
IP
CI
3TC 300 mg
30 Tablet(s)
162.73
191.90
10 %
Coated tablets: Lamivudinum 300 mg
ViiV Healthcare GmbH
A / SO
FB
G
IP
CI
3TC
240 ml
50.28
71.10
10 %
Lösung oral: Lamivudinum 10 mg/ml
ViiV Healthcare GmbH
A
FB
G
Abacavir (J05AF06) 2 products
WHO-DDD
DrugBank.ca
IP
CI
Ziagen
-
T
60 Tablet(s)
199.02
232.85
10 %
Coated tablets: Abacavirum 300 mg
ViiV Healthcare GmbH
A / SL
FB
G
IP
CI
Ziagen
240 ml
56.91
78.30
10 %
Solution (oral): Abacavirum 20 mg/ml
ViiV Healthcare GmbH
A / SL
FB
G
Tenofovir Disoproxil (J05AF07) 6 products
WHO-DDD
DrugBank.ca
IP
CI
Viread
-
T
30 Tablet(s)
445.73
486.90
20 %
Coated tablets: Tenofovirum Disoproxilum 245 mg
Gilead Sciences
Switzerland Sàrl
A / SL / SO
FB
G
IP
CI
Tenofovir Sandoz 245 mg
30
227.82
263.35
10 %
Coated tablets: Tenofovirum Disoproxilum 245 mg
Sandoz
Pharmaceuticals AG
● 
A / SL / SG
FB
G
IP
CI
Tenofovir-Mepha
30 Tablet(s)
227.81
263.30
10 %
Coated tablets: Tenofovirum Disoproxilum 245 mg
Mepha Pharma AG
A / SL / SG
FB
G
IP
CI
Tenofovir Viatris 245 mg
30
207.11
242.10
k.A.
Coated tablets: Tenofovirum Disoproxilum 245 mg
Viatris Pharma GmbH
A
FB
G
IP
CI
Tenofovir Viatris 245 mg
30
207.11
242.10
k.A.
Coated tablets: Tenofovirum Disoproxilum 245 mg
Viatris Pharma GmbH
A
FB
G
IP
CI
Tenofovir-Mepha
90 Tablet(s)
k.A.
Coated tablets: Tenofovirum Disoproxilum 245 mg
Mepha Pharma AG
A
FB
G
Emtricitabine (J05AF09) 1 products
WHO-DDD
DrugBank.ca
SIP
IP
CI
Emtriva
30 Capsule(s)
181.54
213.85
10 %
Capsules: Emtricitabinum 200 mg
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
Entecavir (J05AF10) 15 products
WHO-DDD
DrugBank.ca
IP
CI
Baraclude 0.5 mg
30 Tablet(s)
368.09
413.35
10 %
Coated tablets: Entecavirum
Bristol-Myers Squibb SA
A / SL / SO
FB
G
L
IP
CI
Baraclude 1 mg
30 Tablet(s)
464.79
517.60
10 %
Coated tablets: Entecavirum 1 mg
Bristol-Myers Squibb SA
A / SL / SO
FB
G
IP
CI
Entecavir Sandoz 0.5 mg
30 + 30 + 30 + 30 + 30
312.88
356.70
10 %
Coated tablets: Entecavirum
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
CI
Entecavir Sandoz 1 mg
30 + 30 + 30 + 30 + 30
395.06
446.05
10 %
Coated tablets: Entecavirum 1 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
IP
CI
Entecavir-Mepha 0.5mg
30
312.88
356.70
10 %
Coated tablets: Entecavirum
Mepha Pharma AG
A / SL / SG
FB
G
L
IP
CI
Entecavir-Mepha 1.0mg
30
395.06
446.05
10 %
Coated tablets: Entecavirum 1 mg
Mepha Pharma AG
A / SL / SG
FB
G
IP
CI
Baraclude 0.05 mg/mL
210 ml
k.A.
Solution (oral): Entecavirum
Bristol-Myers Squibb SA
A
FB
G
IP
CI
Baraclude 0.5 mg
30
312.88
356.70
10 %
Coated tablets: Entecavirum
APS-Arzneimittel-
Parallelimport-
Service AG
A / SL / SO
FB
G
L
IP
CI
Baraclude 1 mg
30
434.56
486.60
10 %
Coated tablets: Entecavirum 1 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A / SL / SO
FB
G
IP
CI
Baraclude 0.5 mg
30
k.A.
Coated tablets: Entecavirum
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
CI
Baraclude 0.5 mg
30
k.A.
Coated tablets: Entecavirum
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
Baraclude 1 mg
30
k.A.
Coated tablets: Entecavirum 1 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
Baraclude 1 mg
30
k.A.
Coated tablets: Entecavirum 1 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
CI
Entecavir Sandoz 0.5 mg
30
k.A.
Coated tablets: Entecavirum
Sandoz
Pharmaceuticals AG
A
FB
G
IP
CI
Entecavir Sandoz 1 mg
30
k.A.
Coated tablets: Entecavirum 1 mg
Sandoz
Pharmaceuticals AG
A
FB
G
Telbivudine (J05AF11) 1 products
WHO-DDD
DrugBank.ca
L
IP
CI
Sebivo 600 mg
28 Tablet(s)
411.72
464.20
10 %
Coated tablets: Telbivudinum 600 mg
Viatris Pharma GmbH
A / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home